Our initial consideration is safety and quality.
RIGVIR® contains an adapted live enterovirus, which is oncotropic and oncolytic, non-pathogenic and non-genetically modified. RIGVIR® does not contain antibiotics, stimulants or potentially toxic substances.
RIGVIR® demonstrates an outstanding safety profile. More than 700 patients participated in RIGVIR® clinical studies. No serious adverse effects were recorded, and the most common side effect was a subfebrile temperature.
Not unlike other medicines, RIGVIR® may cause side effects. These potential side effects are short-term and do not require treatment. The most common side effect is a subfebrile temperature lasting 1-3 days.
If you think a medication has caused a side effect, please check the medication’s package leaflet for information on how to report it.
You can usually report side effects by filling in a form online or with your doctor or local pharmacist. For more details, and to report a side effect online, please check the website of your national health authority.
You can also report side effects directly to Marketing Authorization Holder – rigvir@rigvir.com or by filling in side effect reporting form.